Novo Nordisk (NYSE:NGO) is one of them A stock that should double in 3 years. On February 4, Novo Nordisk projected 10% sales growth in 2025, driven by its obesity and diabetes portfolio. The company’s obesity care sales reached DKK 82 billion, marking a significant increase since 2019 and expanding its reach to an additional 16 million patients. Financial results exceeded expectations with reported EPS of $1, although gross margin declined to 81% due to manufacturing acquisition and restructuring costs.
The year was highlighted by major regulatory and pipeline milestones, including FDA approval and the successful launch of the Vigo pill, the first oral GLP-1 for weight management. Clinical data for CagriSema showed better weight loss and glycemic control than semaglutide, and the company is making progress with its next-generation therapy, zingamtide. Additionally, Novo Nordisk is expanding its focus to rare diseases and cardiovascular comorbidities, with multiple Phase III studies and regulatory decisions expected through 2026.
A leadership transition has also been confirmed, with Jamie Miller and Hong Chu joining the executive team as several long-time leaders leave. For 2026, Novo Nordisk ( NYSE:NVO ) issued a cautious financial outlook, suggesting a decline in adjusted sales and operating profit of 5% to 13% at constant exchange rates. The forecast accounts for significant price violations in the United States and patent expirations in international markets, although the company is focused on volume growth and long-term strategic aspirations that will be unveiled during its upcoming capital markets day.
Pixabay/Public Domain
Novo Nordisk (NYSE:NVO), together with its subsidiaries, engages in R&D, manufacturing and distribution of pharmaceutical products. It has two parts: obesity and diabetes care and rare disease.
While we acknowledge the potential of NVO as an investment, we believe that some AI stocks offer more potential and less risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: The 40 most popular stocks among hedge funds heading into 2026 and 10 stocks with explosive growth potential.
Disclosure: None. Follow the inside port on Google News.
